Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM Enters Global Supply Agreements with Telix Pharmaceuticals for Clinical and Commercial Use of ITM\u2019s n.c.a. Lutetium-177","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Telix and Merck to Commence Pan-Cancer Clinical Combination Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in CUPID Study of Telix\u2019s Targeted Alpha Therapy Candidate for Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Telix and Merck to Commence Pan-Cancer Clinical Combination Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"ATONCO","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in ProstACT Program for Prostate Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Eckert & Ziegler Strahlen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"SHINE Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Telix and SHINE Partner for Lutetium-177 Supply","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telix Advances Development of Glioblastoma Therapy Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Phase II Renal Cancer Theranostics Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Monrol","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Monrol is Partnering With Telix Pharmaceuticals, Supplying Lutetium nca Lu 177 for the Manufacturing of Clinical Doses for the Phase II STARLITE 2 Study At MSK and Manufacturing Clinical Doses for Telix\u2019s Phase III ZIRCON Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in PII 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"$5.0 million","newsHeadline":"Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Expanded Indication for Telix's Illuccix\u00ae to Include Patient Selection for PSMA-Directed Radioligand Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Peptide","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Telix to Supply Bayer with Illuccix\u00ae for Global Phase III Prostate Cancer Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"QSAM Biosciences","pharmaFlowCategory":"D","amount":"$125.1 million","upfrontCash":"$2.0 million","newsHeadline":"Telix Announces Proposed Acquisition of QSAM Biosciences and its Lead Therapy Candidate, CycloSam\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"QSAM Biosciences","pharmaFlowCategory":"D","amount":"$123.1 million","upfrontCash":"$33.1 million","newsHeadline":"Telix Signs Agreement to Acquire QSAM Biosciences and its Bone Cancer Targeting Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix\u2122) for Imaging of Kidney Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Telix Pharmaceuticals

    Menu

    Telix Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Telix Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Telix Signs Agreement to Acquire QSAM Biosciences and its Bone Cancer Targeting Platform

              Details:

              Through the acquisition, Telix Pharmaceuticals have access to lead investigational drug Cycloslam (samarium-153-DOTMP) for the treatment of therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

              Lead Product(s): Samarium-153-DOTMP

              Therapeutic Area: Oncology Product Name: CycloSam

              Highest Development Status: Phase I Product Type: Small molecule

              Recipient: QSAM Biosciences

              Deal Size: $123.1 million Upfront Cash: $33.1 million

              Deal Type: Acquisition February 07, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Telix Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer

              Details:

              TLX250-CDx (89Zr-DFO-girentuximab) PET/CT imaging has the potential to improve patient care by serving as a “molecular biopsy” that could be used to guide surveillance, further imaging, or biopsy across all stages of disease.

              Lead Product(s): 89Zr-DFO-girentuximab

              Therapeutic Area: Oncology Product Name: TLX250-CDx

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Telix Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

              Details:

              TLX250-CDx (89Zr-DFO-girentuximab) is a large molecule drug candidate, which is currently being evaluated for the treatment of clear cell renal cell carcinoma via intravenous infusion.

              Lead Product(s): 89Zr-DFO-girentuximab

              Therapeutic Area: Oncology Product Name: TLX250-CDx

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Telix Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Telix Announces Proposed Acquisition of QSAM Biosciences and its Lead Therapy Candidate, CycloSam®

              Details:

              Through the acquisition, Telix gain rights to CycloSam (samarium-153-DOTMP), a novel, de-risked clinical asset that has the potential to deliver tangible improvements of prior bone-seeking agents.

              Lead Product(s): Samarium-153-DOTMP

              Therapeutic Area: Oncology Product Name: CycloSam

              Highest Development Status: Phase I Product Type: Small molecule

              Recipient: QSAM Biosciences

              Deal Size: $125.1 million Upfront Cash: $2.0 million

              Deal Type: Acquisition November 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Telix Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability

              Details:

              TLX591 (177Lu-DOTA-TLX591) is first-in-class radio-antibody drug conjugate (rADC) investigational therapy, which is investigated for the the treatment of prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer.

              Lead Product(s): Lutetium-177 Rosopatamab Tetraxetan

              Therapeutic Area: Oncology Product Name: TLX591

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Telix Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma

              Details:

              TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) is one of Telix's lead therapeutic clinical programs and has been granted orphan drug designation in the United States and Europe for glioblastoma therapy.

              Lead Product(s): [131I]Iodo-phenylalanine,Temozolomide

              Therapeutic Area: Oncology Product Name: TLX101

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Telix Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study

              Details:

              Under the agreement, Telix will suppy Illuccix (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injection) for the Phase III ARASTEP study, investigating Bayer's ARi Nubeqa (darolutamide) plus ADT versus ADT alone in hormone-sensitive prostate cancer.

              Lead Product(s): Darolutamide,Androgen Deprivation Therapy

              Therapeutic Area: Oncology Product Name: Nubeqa

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Bayer AG

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 08, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Telix Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical

              Details:

              LY3012207 (olaratumab) is a mAb targeting PDGFRα. It was granted accelerated approval in the U.S. and conditional approval in the EU based on Phase II trial data which showed a 1-year survival benefit in patients with STS, when given in combination with standard chemotherapy.

              Lead Product(s): Olaratumab,Doxorubicin Hydrochloride

              Therapeutic Area: Oncology Product Name: LY3012207

              Highest Development Status: Preclinical Product Type: Large molecule

              Recipient: Eli Lilly

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 17, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Telix Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

              Details:

              Illuccix (gallium Ga 68 gozetotide) binds to PSMA. It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Gallium 68 (Ga 68) is a β+ emitting radionuclide that allows positron emission tomography.

              Lead Product(s): Gallium Ga 68 Gozetotide

              Therapeutic Area: Oncology Product Name: Illuccix

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 16, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Telix Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU

              Details:

              TLX250-CDx (89Zr-DFO-girentuximab) PET/CT imaging has the potential to improve patient care by serving as a “molecular biopsy” that could be used to guide surveillance, further imaging, or biopsy across all stages of disease.

              Lead Product(s): 89Zr-DFO-girentuximab

              Therapeutic Area: Oncology Product Name: TLX250-CDx

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY